{"nctId":"NCT01138514","briefTitle":"Clinical Study Between Two Clindamycin 1%/Benzoyl Peroxide 5% Topical Gels","startDateStruct":{"date":"2009-10"},"conditions":["Acne Vulgaris"],"count":1555,"armGroups":[{"label":"Clindamycin 1%/Benzoyl Peroxide 5%","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo)"]},{"label":"Reference Product","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Clindamycin 1% / Benzoyl Peroxide 5% (Benzaclin)"]},{"label":"Vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo)","otherNames":[]},{"name":"Clindamycin 1% / Benzoyl Peroxide 5% (Benzaclin)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy men or women, 12 to 65 years of age\n* Willing to participate and sign provide written consent\n* Moderate to severe acne\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* History of unresponsiveness or hypersensitivity to clindamycin, benzoyl peroxide or lincomycin\n* Use of systemic, topical or facial products which may interfere with the study\n* Participation in any clinical study in the 30 days prior to study entry\n* Prolonged exposure to sunlight or excessive exposure to UV lights\n* Chronic use of NSAIDS","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"65 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Inflammatory Lesions","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.87","spread":"27.38"},{"groupId":"OG001","value":"80.86","spread":"24.65"},{"groupId":"OG002","value":"45.60","spread":"44.01"}]}]}]},{"type":"PRIMARY","title":"Percent Change From Baseline in Non-inflammatory Lesions","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.21","spread":"30.48"},{"groupId":"OG001","value":"70.02","spread":"28.77"},{"groupId":"OG002","value":"36.16","spread":"48.15"}]}]}]},{"type":"SECONDARY","title":"Number of Participant With Clinical Success on the Investigator's Global Assessment (IGA)","description":"Clinical success was defined as a score of clear (0) or almost clear (1) at Week 10.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"247","spread":null},{"groupId":"OG001","value":"234","spread":null},{"groupId":"OG002","value":"79","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":522},"commonTop":["Acne","Application Site dryness"]}}}